Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jan 27, 2022
Regulation
Immunocore charts path to broader indications, new targets after first FDA approval
Kimmtrak authorization brings the first uveal melanoma therapy and a new immuno-oncology modality to market
BioCentury | Dec 5, 2020
Product Development
Bispecifics spring ahead at this year’s ASH, SITC
First-in-human results at fall conferences reveal rapid expansion in the target space for bispecifics
BioCentury | Dec 6, 2019
Targets & Mechanisms
Bispecifics and allogeneics steal the spotlight from autologous CAR Ts
At ASH19, it’s all about how to replace first-gen CAR Ts with something better
BioCentury | Oct 20, 2017
Product R&D
Fighting cancer by mouth
How Vaximm's oral delivery tech may give its cancer vaccines an efficacy boost
BioCentury | Jul 20, 2017
Product R&D
Eureka moment for TCR mimics
How Eureka is developing high affinity TCR-like antibodies
Items per page:
1 - 10 of 50